SPPI

Spectrum Pharmaceuticals Inc

SPPI

Market cap $211M

Overview Fund Activity

Delisted

SPPI was delisted on the 31st of July, 2023.

Back to rankings

About: Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.

Employees: 86

Healthcare Drug Manufacturers - General

Financial journalist opinion

ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.

ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important September 24, 2025 lead plaintiff deadline.

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPI

LOS ANGELES , Sept. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum " or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPI

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Sept. 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , Aug. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important September 24, 2025 lead plaintiff deadline. So What: If you purchased Spectrum Pharmaceuticals common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important September 24, 2025 lead plaintiff deadline. So What: If you purchased Spectrum Pharmaceuticals common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit

SPPI New Lead Plaintiff Deadline: Contact Robbins LLP for Information About Leading the Class Action Against SPPI

SAN DIEGO , Aug. 26, 2025 /PRNewswire/ -- Robbins LLP reminds investors who purchased shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between March 17, 2022 and September 22, 2022, of the reopening of the Lead Plaintiff appointment process in the pending securities class action. Spectrum purports to be a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

SPPI New Lead Plaintiff Deadline: Contact Robbins LLP for Information About Leading the Class Action Against SPPI

NASDAQ: SPPI DEADLINE REMINDER: Berger Montague Reminds Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors of Important Class Action Lawsuit Deadline

PHILADELPHIA , Aug. 25, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.

NASDAQ: SPPI DEADLINE REMINDER: Berger Montague Reminds Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors of Important Class Action Lawsuit Deadline

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

NEW YORK, Aug. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

See News Rankings

Charts implemented using Lightweight Charts™